ReviewCurrent hepatology reports2020
Hemodynamic and Systemic Effects of Albumin in Patients with Advanced Liver Disease.
Review in Current hepatology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Prognostic value of albumin-bilirubin grade in patients with pancreatic cancer: A systematic review and meta-analysis.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Pooled it
- Understanding the microRNA signature associated with Reye's syndrome.Protoplasma · 2026Review
- Management of endothelial dysfunction in septic shock: role of albumin administration.Journal of intensive care · 2025Article
- Albumin prevents kidney injury but is underutilized in a cohort of patients undergoing large-volume paracentesis.Hepatology communications · 2025Article
- Epidemiology and Risk Prediction Model of Multidrug-Resistant Organism Infections After Liver Transplant Recipients: A Single-Center Cohort Study.Bioengineering (Basel, Switzerland) · 2025Article
- Explainable machine learning model of coronary artery disease combined with diabetes: development and validation study.Frontiers in cardiovascular medicine · 2025Article
- Endothelial Dysfunction and Liver Cirrhosis: Unraveling of a Complex Relationship.International journal of molecular sciences · 2024Review
- Role of albumin infusion in cirrhosis-associated complications.Clinical and experimental medicine · 2024Review
- Serum Albumin Levels: A Biomarker to Be Repurposed in Different Disease Settings in Clinical Practice.Journal of clinical medicine · 2023Review
- Successful treatment of acute-on-chronic liver failure secondary to alcoholic cirrhosis with glucocorticoids and albumin: a case report.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2022Article
- Bile Acids, Liver Cirrhosis, and Extrahepatic Vascular Dysfunction.Frontiers in physiology · 2021Review
- Oxidative Stress Markers in Inflammatory Bowel Diseases: Systematic Review.Diagnostics (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose of Review: Albumin administration is recommended to prevent or treat specific complications of decompensated cirrhosis based on its capacity to expand plasma volume. However, the molecule also has many other biological properties that are unrelated to the oncotic activity. The purpose of this review is to examine the hemodynamic and systemic effects of albumin administration in patients with decompensated cirrhosis. Recent Findings: Besides plasma expansion, albumin appears to act against inflammation, facilitate immunocompetence, and improve cardiac and endothelial function, thus antagonizing critical steps in the pathophysiological cascade underlying decompensated cirrhosis. Summary: Increasing knowledge of the pathophysiological mechanisms of the disease, as well the pleiotropic properties of the molecule, provides the rationale for considering albumin as a multi-target disease-modifying agent in decompensated cirrhosis. Both oncotic and non-oncotic properties likely concur with the clinical benefits of long-term albumin administration recently demonstrated in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.